Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
October 1, 2025

Upregulation of SLC25A1 by MAZ reprograms fatty acid synthesis and fuels LUAD malignancy.

View Full Paper
Ask AI
Bookmark
Share

Authors

XLXiaomeng LiJLJing Li

Discussion

Loading...

Member takes

Overview

Investigation reveals that MAZ regulates SLC25A1 expression and enhances fatty acid synthesis in LUAD, suggesting new therapeutic strategies.

Key Points

  • Upregulation of SLC25A1 in LUAD correlates with poor prognosis and promotes cell proliferation.
  • In this study, MAZ was shown to positively regulate SLC25A1, boosting fatty acid synthesis in LUAD cells.
  • In vivo studies demonstrated that MAZ accelerates the malignant progression of LUAD via SLC25A1 regulation.
  • The findings suggest MAZ and SLC25A1 as potential targets for therapeutic strategies in LUAD patients.

Cite This Study

Li et al. (2025) studied this question.

synapsesocial.com/papers/68dd89e6fe798ba2fc497f82https://doi.org/10.4149/gpb_2025036
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1SLC25A39 overexpression exacerbates lung adenocarcinoma progression and is negatively regulated by AFG3L22025
  2. 2SLC25A20 promotes tumor growth by reprogramming energy metabolism in lung adenocarcinoma2026
  3. 3Molecular mechanisms of MAZ targeting up-regulation of NDUFS3 expression to promote malignant progression in melanoma2024
  4. 4MZF1-AS1 promotes proliferation and invasion of lung adenocarcinoma cells by regulating the miR-27b-3p/KRAS axis2026
  5. 5The role of SLC2A1 in lung adenocarcinoma: From tumorigenesis to patient survival2025